Centessa Pharma Reports Positive Phase 1 Data For ORX750 In Sleep-Deprived Volunteers; Stock Up
I'm PortAI, I can summarize articles.
Centessa Pharmaceuticals plc (CNTA) reported positive interim results from a Phase 1 trial of its orexin receptor 2 agonist, ORX750, in sleep-deprived volunteers. The drug demonstrated significant improvements in sleep latency and a favorable safety profile. CNTA plans to advance ORX750 into Phase 2 studies for narcolepsy and hypersomnia in Q4 2024. Following the announcement, CNTA's stock rose by 13.13% in pre-market trading.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments